Brivio, E., Pennesi, E., Willemse, M. E., Huitema, A. D. R., Jiang, Y., van Tinteren, H. D. R., van der Velden, V. H. J., Beverloo, B. H., den Boer, M. L., Rammeloo, L. A. J., Hudson, C., Heerema, N., Kowalski, K., Zhao, H., Kuttschreuter, L., Bautista Sirvent, F. J., Bukowinski, A., Rizzari, C., Pollard, J., … Zwaan, C. M. (2024). Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. Journal of Clinical Oncology, 42(7), 821–831. https://doi.org/10.1200/jco.23.00897

Mok, S., & Fidock, D. A. (2024). Determinants of piperaquine-resistant malaria in South America. The Lancet Infectious Diseases, 24(2), 114–116. https://doi.org/10.1016/s1473-3099(23)00564-9

Dioun, S., Chen, L., De Meritens, A. B., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Pua, T., Hershman, D. L., & Wright, J. D. (2024). Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecologic Oncology, 182, 70–74. https://doi.org/10.1016/j.ygyno.2023.12.027

Hagenah, L. M., Dhingra, S. K., Small-Saunders, J. L., Qahash, T., Willems, A., Schindler, K. A., Rangel, G. W., Gil-Iturbe, E., Kim, J., Akhundova, E., Yeo, T., Okombo, J., Mancia, F., Quick, M., Roepe, P. D., Llinás, M., & Fidock, D. A. (2024). Additional PfCRT mutations driven by selective pressure for improved fitness can result in the loss of piperaquine resistance and altered Plasmodium falciparum physiology. MBio, 15(1). https://doi.org/10.1128/mbio.01832-23

Zuccarello, E., Zhang, H., Acquarone, E., Pham, D., Staniszewski, A., Deng, S.-X., Landry, D. W., Arancio, O., & Fiorito, J. (2023). Optimizing metabolic stability of phosphodiesterase 5 inhibitors: Discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity. Bioorganic & Medicinal Chemistry Letters, 92, 129409. https://doi.org/10.1016/j.bmcl.2023.129409

de Botton, S., Fenaux, P., Yee, K., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan, M., Blum, W., Cilloni, D., Hiwase, D. K., … Cortes, J. (2023). Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances, 7(13), 3117–3127. https://doi.org/10.1182/bloodadvances.2022009411

Wicht, K. J., Small-Saunders, J. L., Hagenah, L. M., Mok, S., & Fidock, D. A. (2022). Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials. The Journal of Infectious Diseases, 226(11), 2021–2029. https://doi.org/10.1093/infdis/jiac365

Small-Saunders, J. L., Hagenah, L. M., Wicht, K. J., Dhingra, S. K., Deni, I., Kim, J., Vendome, J., Gil-Iturbe, E., Roepe, P. D., Mehta, M., Mancia, F., Quick, M., Eppstein, M. J., & Fidock, D. A. (2022). Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance. PLOS Pathogens, 18(2), e1010278. https://doi.org/10.1371/journal.ppat.1010278